Yahoo · Nov 4, 2026
Seres Therapeutics: Q3 Earnings Snapshot
(MCRB) on Wednesday reported a loss of $16.The Cambridge, Massachusetts-based company said it had a loss of $1.
NASDAQ · MCRB
Healthcare · Biotechnology
$1.33
Down-$0.09 (-6.77%)
Updated Nov 21, 2026, 1:41 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MCRB
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
MCRB closed at $1.33 after 20 trading sessions, down 36.36% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $1.47 | $1.47 | $1.31 | $1.33 | 54.69K |
| Nov 18, 2026 | $1.43 | $1.58 | $1.413 | $1.44 | 42.97K |
| Nov 17, 2026 | $1.39 | $1.50 | $1.33 | $1.41 | 55.58K |
| Nov 16, 2026 | $1.38 | $1.70 | $1.38 | $1.41 | 186.62K |
| Nov 13, 2026 | $1.38 | $1.48 | $1.3246 | $1.40 | 59.95K |
| Nov 12, 2026 | $1.48 | $1.48 | $1.30 | $1.41 | 74.19K |
| Nov 11, 2026 | $1.54 | $1.585 | $1.35 | $1.50 | 240.39K |
| Nov 10, 2026 | $1.68 | $1.74 | $1.55 | $1.56 | 39.48K |
| Nov 9, 2026 | $1.94 | $2.05 | $1.68 | $1.70 | 184.23K |
| Nov 6, 2026 | $2.13 | $2.26 | $1.96 | $1.98 | 82.28K |
| Nov 5, 2026 | $2.15 | $2.20 | $2.005 | $2.09 | 94.59K |
| Nov 4, 2026 | $1.9941 | $2.14 | $1.76 | $2.09 | 94.99K |
| Nov 3, 2026 | $1.97 | $1.98 | $1.85 | $1.96 | 53.11K |
| Nov 2, 2026 | $1.84 | $2.00 | $1.81 | $1.83 | 44.16K |
| Oct 30, 2026 | $1.92 | $1.92 | $1.75 | $1.77 | 120.11K |
| Oct 29, 2026 | $1.90 | $2.0293 | $1.81 | $1.95 | 78.51K |
| Oct 28, 2026 | $1.77 | $1.93 | $1.675 | $1.79 | 87.5K |
| Oct 27, 2026 | $2.00 | $2.00 | $1.70 | $1.80 | 165.35K |
| Oct 26, 2026 | $2.11 | $2.185 | $1.98 | $1.98 | 53.07K |
| Oct 23, 2026 | $2.13 | $2.17 | $2.00 | $2.09 | 69.71K |
The latest Smart Investors Daily articles mentioning MCRB.
Company
Market Activity
Research & News
MCRB research
Company profile and research snapshot.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2026 | Canaccord Genuity | Buy | — |
| Sep 24, 2025 | Canaccord Genuity | Buy | — |
| May 8, 2025 | Chardan Capital | Neutral | — |
| Mar 20, 2025 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 4, 2026
(MCRB) on Wednesday reported a loss of $16.The Cambridge, Massachusetts-based company said it had a loss of $1.
Yahoo · Nov 4, 2026
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to submit plans for the next irEC study design to the FDA in Q1 2027 Study builds on encouraging investigator-sponsored trial (IST) results, in which 12 of 15 participants (80%) with moderate-to-severe irEC achieved an immunosuppressive-free clinical response of diarrhea following tre
Benzinga · Nov 4, 2026
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.63) per share which missed the analyst consensus estimate of $(1.00) by 63 percent. This is a 273.4 percent decrease over earnings of $0.94 per share
Yahoo · Nov 3, 2026
Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and reducing systemic inflammation CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Pha
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning MCRB.